Campus Units

Veterinary Diagnostic Laboratory, Veterinary Diagnostic and Production Animal Medicine

Document Type

Article

Publication Version

Published Version

Publication Date

6-8-2012

Journal or Book Title

Vaccine

Volume

30

Issue

27

First Page

4079

Last Page

4085

DOI

10.1016/j.vaccine.2012.04.022

Abstract

Porcine circovirus associated disease (PCVAD) encompasses a group of syndromes linked to infection with porcine circovirus type 2 (PCV2). Based on the hypothesis that the immune responses to vaccination versus infection are quantitatively and qualitatively different, the objective of this study was to evaluate immunity, virus replication and disease protection in pigs vaccinated with PCV2 capsid protein (CP) and during infection. The disease model included dual infection with PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV), a virus known to enhance disease progression and severity. The principal effect of PRRSV infection was to increase peak PCV2 viremia by almost 40-fold; however, PCV2 failed to show a reciprocal effect on PRRSV. In vaccinated pigs, there was no evidence of disease or PCV2 replication following dual virus challenge. Immunity following vaccination favored PCV2 neutralizing activity; whereas, PCV2 infection and disease produced high levels of non-neutralizing antibody, primarily directed against a polypeptide in the C-terminal region of CP. These results support the notion that the magnitude of the total antibody response cannot be used as a measure of protective immunity. Furthermore, protection versus disease lies in the immunodominance of specific epitopes. Epitope specificity should be taken into consideration when designing PCV2 vaccines.

Comments

This article is published as Trible, Benjamin R., Alejandro Ramirez, Andrew Suddith, Alexandra Fuller, Maureen Kerrigan, Richard Hesse, Jerome Nietfeld, Baoqing Guo, Eileen Thacker, and Raymond R.R. Rowland. "Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition." Vaccine 30, no. 27 (2012): 4079-4085. DOI: 10.1016/j.vaccine.2012.04.022.

Rights

Works produced by employees of the U.S. Government as part of their official duties are not copyrighted within the U.S. The content of this document is not copyrighted.

Language

en

File Format

application/pdf

Share

COinS